Immune cell boost shows promise for leukemia relapse after transplant

NCT ID NCT04024761

First seen Jan 04, 2026 · Last updated May 08, 2026 · Updated 18 times

Summary

This early-phase study tests a new type of immune cell (CIML NK cells) combined with a low-dose drug (IL-2) in people whose leukemia or related blood cancers have returned after a stem cell transplant. The goal is to find a safe dose and see if it can put the cancer back into remission. The study includes adults (18+) and teens (12+) with certain blood cancers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Boston Children's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.